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combined stroke and death rate.
Results: In total 269 patients had complete data and were included
in the analysis.The demographic and clinical data were similar in the
groups The 30-day combined stroke and death rate did not differ
signiﬁcantly between the groups; 0% (0/12) in the group treated 0e
2 days, versus 3.9% (3/76), 2.9% (2/68), and 5.3% (6/113) for the
patients treated at 3e7 days, 8e14 days and 15e180 days
respectively (p ¼ 0.759). The 30-day stroke and death rate in the
secondary analysis were also similar between groups; 3.4% (3/88),
2.9% (2/68), 6.3% (3/48), and 4.6% (3/65) respectively, (p¼ 0.813).
Conclusion: In this national registry study, limited by small
numbers, patients that underwent urgent CAS after onset of a
neurologic event had no additional risk of suffering from a peri-
operative complication.Lessons from 500 Adverse Event Reports on SFA Stents from
MAUDE Database-need for Action by ESVS?
R. Gambhir
King’s College Hospital, London, UK
Introduction: When a Boeing aircraft develops a problem at New
York, within the next 24 hrs the whole Boeing ﬂeet, the world over,
gets an alert with initial defect report, cause and a ﬁx. On the
other hand when the trigger mechanism of delivery system of an
SFA stent fails in a London Hospital, nothing similar happens. FDA
mandates the manufacturers to report all adverse events within 30
days on the MUADE database. An analysis of 500 adverse event
reports on SFA stents reveals lessons for the vascular societies and
calls for uniﬁed action for the sake of patient safety.
Methods: MAUDE database was searched for all adverse event
reports on SFA stents from 01/04/2012 to 31/03/2014. Each report
lists the event description, the date, patient injury, intervention if
required and the manufacturer’s narrative.
Results: 500 SFA stent adverse reports were recorded and ana-
lysed. All known manufacturers were listed. Adverse reports from
2 stent manufacturers were signiﬁcantly more than the others. A
similar deployment failure was reported for over 1 year by one
manufacturer. More than 1/3rd of the reported cases had either a
failure in deployment of the stent or retrieval of the standard
delivery system (sds). In another 1/3rd the stent was damaged
after deployment-twisted, torqued, fractured, or occluded. In the
remaining 1/3rd there were multitudes of problems from breakage
of sds components and their retention within the patient to
dislodgment.
Adverse patient effects included Acute Limb ischemia, limb loss
and death. Majority required endovascular intervention, failing
which an open procedure was performed in 20% of patients.
Analysis of manufacturer’s narrative rarely revealed no attrib-
utable cause, the malfunction, mal-deployment was labeled as
procedure related and not device related. The manufacturer’s
narrative often stated that the device met pre-release speciﬁca-
tions and no manufacturing defect could be identiﬁed.
Conclusion: A review of adverse event reports form manufac-
turer’s clearly indicates that the adverse event was procedure
related and probably due to the operator not exercising due care
or not following the IFU. There is a need for the societies to take
a lead in user adverse event reporting, analysis and communi-
cating these to the centre’s on a deﬁnitive time scale in a more
open and uniﬁed manner to prevent patient harm and improve
outcomes.Impact of Early Pelvic and Lower Limbs Reperfusion and
Aggressive Perioperative Management on Spinal Cord Ischemia
During Thoracoabdominal Aortic Aneurysm Endovascular Repair
B. Maurel, N. Delclaux, J. Sobocinski, A. Hertault, T. Martin-Gonzalez,
R. Spear, M. Le Roux, R. Azzaoui, S. Haulon
CHRU, Lille, France
Introduction: Spinal cord ischemia (SCI) is a devastating compli-
cation following thoracoabdominal aortic aneurysm (TAAA)
endovascular repair. In an attempt to reduce its occurrence, we
have modiﬁed our implantation protocol in January 2010 by
withdrawing all large sheaths from the iliac arteries as soon as
possible during the procedure. In addition, we have also modiﬁed
our perioperative protocol (aggressive blood and platelet trans-
fusion, median arterial pressure monitoring >80 mmHg, and sys-
tematic cerebrospinal ﬂuid drainage except for type 4 TAAA).
Methods: Between October 2004 and December 2013, we have
performed 204 TAAA endovascular repairs with custom made
devices manufactured with branches and fenestrations to perfuse
the visceral vessels. Data from all patients were prospectively
collected in an electronic database. We compared the early out-
comes of patients treated before (group 1, 43 patients) and after
(group 2, 161 patients) modiﬁcation of our implantation and
perioperative protocols.
Results: Group 1 and 2 patients had similar comorbidities (median
age at repair 70.9 years [65.2e77]), aneurysm characteristics
(median diameter 58.5 mm [53e65]), and length of procedure
(median 190 min [150e240]). The in-hospital mortality rate was
11.6% in group 1 vs. 5.6% in group 2 respectively (RR ¼ 0.481
[0.17e1.36]; p ¼ 0.09). The spinal cord ischemia rate was 14% vs.
1.2% (RR ¼ 1.148 [1.016e1.296]; p ¼ 0.001) respectively. If we
exclude Type 4 TAAA from this analysis, the spinal cord ischemia
rate was 25% (6/24 patients) in group 1 vs. 2.1% (2/95 patients) in
group 2 (RR ¼ 1.306 [1.034e1.648]; p < 0.001) respectively.
Conclusion: Early restoration of arterial ﬂow to the pelvis and
lower limbs and aggressive perioperative management signiﬁ-
cantly reduces SCI following TAAA endovascular repair. With this
modiﬁed approach, extensive TAAA endovascular repairs are
associated with low rates of SCI.Endovascular Management of Rupture in Acute Type B Aortic
Dissections
E. Faure, L. Canaud, J.P. Becquemin, P. Alric
Department of Thoracic and Vascular Surgery; University Hospital, Montpellier,
France
Introduction: Reports of thoracic endovascular aortic repair
(TEVAR) for complicated acute type B dissection bring together a
large range of clinical presentations.With a 50% of 30-day mortality
rate whenmanaged with open surgery, rupture is themost dramatic
complication of acute type B dissections. We investigated the out-
comes of TEVAR for acute type B dissection complicated by rupture
(R-ABD) to assess the results of this particularly critical subgroup.
Methods: A review of consecutive TEVAR for R-ABD in two tertiary
centers was performed using prospectively maintained database.
Results: Between 2000 and 2014, 24 patients (mean age 68 years;
14 males) underwent TEVAR for R-ABD. Sixteen (67%) were in
shock (Systolic blood pressure <80 mmHg) before surgery and 20
required chest drainage for hemothorax. Proximal entry tear was
in zone 2 in 7 (29%) and 3 in 17 (71%). Five patients required
coverage of the left subclavian artery for adequate proximal
344 Abstractslanding zone, of whom 3 with concomitant extra-anatomic
debranching of the supra-aortic vessels. Technical success was
achieved in 100%. The 30-day mortality rate was 16.7% (n ¼ 4).
Two patients had paraplegia. Neither stroke nor renal insufﬁciency
requiring new dialysis occurred. During a mean follow-up of 28
months, another death in relation with dissection occurred and 8
patients (33%) required reintervention. All reintervention were
managed by endovascular means. At last follow up CT-scan, 8
patients (33%) had complete remodeling of the aortic wall.
Conclusion: This study conﬁrms the feasibility of TEVAR for R-BAD
and its lower perioperative morbidity and mortality rate compared
to open surgery, reducing by more than 2 third the 30-day mor-
tality. However the rate of reintervention is high and a long term
follow up is mandatory.
Dipeptidyl Peptidase-4 Inhibitor Alogliptin Prevents Further
Dilatation of Abdominal Aortic Aneurysm Through Anti-oxidant
and Anti-inﬂammatory Effect in Rats
J. Yu
Kobe University Graduate School of Medicine, Japan
Introduction: Dipeptidyl peptidase-4 inhibitor alogliptin has been
proved to prevent abdominal aortic aneurysm (AAA) formation.
However, the mechanism of alogliptin on aneurysm development
has not been sufﬁciently investigated. The objective of this study
was to determine how alogliptin prevents further dilation of AAA
development mimicking clinical setting.
Methods: The AAA model induced with intraluminal elastase and
extraluminal calcium chloride was created in 42 rats. Forty-two rats
were divided 3 groups: a low-dose of alogliptin group (Group LD; 1
mg/kg/day), a high-dose group (Group HD; 3 mg/kg/day), and a
control group (Group C, water). Alogliptin administration by gastric
gavage once per daywas started on 7 days after aneurysm formation
(Dilatation ratio: 158.9 7.7%). On day 14, reactive oxygen species
(ROS) expression and the oxidation product of DNA 8-
hydroxydeoxyguanosine (8-OHdG) was measured. As ROS have
been reported to activate ERK pathway which is important modu-
lator of MMPs and inﬂammatory cytokines, MMP expression and
inﬂammatory response were also analyzed along with ERK evalua-
tion. Histopathological examination was performed on day 28, and
the AAA dilatation ratio was calculated to evaluate alogliptin pro-
tective effect.
Results: On day 14, ROS expression and 8-OHdG positive cells in
aneurysm walls were decreased by alogliptin treatment (ROS
expression: 4.4  0.6 in Group C, 3.2  0.1 in Group LD, and 2.7 
0.3 in Group HD, p < 0.001; 8-OHdG-positive cells: 167.4  6.9
cells in Group C, 102.7  19.9 cells in Group LD, and 64.7  2.7
cells in Group HD, p < 0.001). Western blot analysis showed
decrease ERK levels in treatment groups compared with in control
group. The treatment signiﬁcantly reduced mRNA expression of
MMPs, TNF-a and MCP-1 in aneurysm walls. Immunohistochemical
staining for CD68 demonstrated the decrease of macrophage
inﬁltration in aneurysm wall with treatment groups. On day 28, the
aortic wall in groups LD and HD were less dilated, and had higher
elastin content than those in Group C (Dilatation ratio: 199.2 
10.8% in Group C, 170.0  4.4% in Group LD, and 155.1  2.3% in
Group HD, p < 0.001).
Conclusion: Alogliptin treatment starting after aneurysm forma-
tion inhibits further dilation in rat model through anti-oxidant and
anti-inﬂammatory effect. Inhibition of ERK activation by reducing
oxidative stress prevented inﬂammatory response and matrix
degeneration, resulting in prevention of the aortic dilatation.High Frequency of AAA in the North of Sweden Not Explained by
Higher AAA Prevalence Among Siblings or Smoking
J. Forsberg *, A. Linné *, K. Leander, D. Lindström, R. Hultgren
Dept of Clinical Science and Education, Karolinska Institutet at Södersjukhuset,
Sweden
Introduction: The frequency of Abdominal Aortic Aneurysm (AAA)
is higher in the north region of Sweden compared to the south
with a 38% higher incidence for AAA in men. Smoking is less
common in the north and can subsequently not be responsible for
the increased risk. A strong hereditary trait has been suggested as
an explanation to the regional differences in disease pattern.
Organized screening for AAA in siblings is currently not arranged in
either region. Our aim was to investigate if siblings to AAA-patients
in the north part of Sweden have a higher prevalence of AAA
compared to siblings in the Stockholm region (mid).
Methods: All patients treated for AAA between Jan 2008eAug
2012 at two hospitals covering a large county of the north were
screened for siblings (n ¼ 483). The living siblings residing in the
north were offered an ultrasound scan of the abdominal aorta
preceded by a structured telephone interview regarding health
and medications. Ultrasound was performed by one validated
examiner using both LELE and OTO-technique. The result of the
ultrasound-examination was compared to the previously published
results of the prevalence of AAA in siblings in Stockholm (mid
Sweden).
Results: 379 siblings were included of which 8 had undergone
aortic repair and 8 had a known AAA under surveillance. 363 were
screened with ultrasound. The prevalence of AAA in all siblings was
34/379 (10%, brothers 14%, sisters 6%). There was no difference in
the prevalence of AAA in siblings from north compared to mid
region (p ¼ 0.75). Smoking was as common in both regions among
siblings with AAA.
Conclusion: Our data do not support a strong hereditary trait for
AAA in the north part of Sweden compared to other regions. The
results reinforce the importance of developing structured
screening protocols for ﬁrst degree relatives to AAA patients, since
the prevalence in siblings is strikingly high as compared to the
prevalence of AAA in the general population.Autologous Alternative Veins Do Not Provide Better Mid-term
Outcomes than Prosthetic Conduits for Below Knee Bypass When
Great Saphenous Vein is Unavailable
E.D. Avgerinos, A. Naddaf, U. Sachdev, D. Doucet, A. Mohapatra,
S.A. Leers, R.A. Chaer, M.S. Makaroun
University of Pittsburgh Medical Center, Pittsburg, USA
Introduction: Ipsilateral, single segment great saphenous vein
(GSV) remains the optimal conduit for below knee bypass to treat
critical limb ischemia. There is a need to better deﬁne the beneﬁt
of alternative autologous vein (AAV) segments over contemporary
prosthetic conduits in patients in whom GSV is not available.
Methods: Patients who underwent bypass to below-knee targets
for chronic arterial occlusive disease between 2007e2011 were
retrospectively reviewed and categorized in three groups: GSV;
AAV (small saphenous veins, arm veins or spliced vein segments);
Prosthetic. The primary outcome was graft patency (primary,
assisted primary, secondary). Secondary outcome was limb
salvage. Cox regression models were used to assess the effect of
baseline predictors. Results were considered statistically signiﬁcant
when p-value was <0.05.
